Thymic Stromal Lymphopoietin Protein (TSLP) (Transcript Variant 1)

Catalog No. ABIN2734446

This Recombinant Thymic Stromal Lymphopoietin protein is produced in Escherichia coli (E. coli).

Quick Overview for Thymic Stromal Lymphopoietin Protein (TSLP) (Transcript Variant 1) (ABIN2734446)

Target: Thymic Stromal Lymphopoietin (TSLP)

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Application: Standard (STD), Antibody Production (AbP)

Purity: > 95 % as determined by SDS-PAGE and Coomassie blue staining

Product Details

Protein Characteristics: Transcript Variant 1

Characteristics:

• Recombinant human TSLP (transcript variant 1) protein expressed in E. coli.
• Produced with end-sequenced ORF clone

Endotoxin Level: Endotoxin level is <0.1 ng/μg of protein (<1EU/μg).

Application Details

Application Notes: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Restrictions: For Research Use only

Handling

Buffer: Lyophilized from a 0.2 μM filtered solution of 20 mM phosphate buffer,100 mM NaCl, pH 7.2

Handling Advice: Resuspend the protein in the desired concentration in proper buffer

Storage: -80 °C

Storage Comment: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Target Details

Target: Thymic Stromal Lymphopoietin (TSLP)

Alternative Name: Tslp

Background: This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. Alternative splicing of this gene results in multiple transcript variants.

Molecular Weight: 15 kDa

NCBI Accession: NP_149024